Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELND005 safety extension in Alzheimer's agitation
NCT01766336Phase 2Terminated
- Sponsor
- OPKO Health
- Start
- Jan 2013
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of scyllo-inositol in Alzheimer's disease (AD), sponsored by OPKO Health. Started Jan 2013; status: terminated.
02
Drugs
scyllo-inositol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01766336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01766336.